TRV GP VI’s Tango Therapeutics TNGX Stock Holding History

TRV GP VI’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.07M	Hold	194,174	–	–	2.61%	4
2026 Q1	$4.06M	Hold	194,174	–	–	3%	3
2025 Q4	$1.72M	Hold	194,174	–	–	1.16%	3
2025 Q3	$1.63M	Hold	194,174	–	–	1.49%	3
2025 Q2	$994K	Hold	194,174	–	–	1.55%	4
2025 Q1	$266K	Hold	194,174	–	–	0.63%	4
2024 Q4	$600K	Buy	+194,174	New	+$902K	0.51%	4

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TRV GP VI's TNGX Position: Q2 2026 in Review

TRV GP VI held its Tango Therapeutics (TNGX) position steady in Q2 2026 at 194,174 shares worth $6.07M. The position accounts for 2.61% of the portfolio, ranked #4.

TRV GP VI first reported a position in TNGX in Q4 2024 and has held it in 7 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

TRV GP VI held 194,174 shares of Tango Therapeutics worth $6.07M as of Q2 2026.
TRV GP VI left its Tango Therapeutics share count unchanged in Q2 2026.
Tango Therapeutics made up 2.61% of TRV GP VI's portfolio in Q2 2026, its #4 holding.
TRV GP VI first reported a position in Tango Therapeutics in Q4 2024 and has held it in 7 quarters since.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on TRV GP VI's 13F filing for Q2 2026, filed 10 Aug 2026.